Pharmacology of Empagliflozin

Introduction/Overview

Empagliflozin represents a significant advancement in the therapeutic management of type 2 diabetes mellitus and related cardiorenal conditions. As a member of the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, its introduction marked a paradigm shift from purely glucocentric treatment strategies to approaches offering broader metabolic and organ-protective benefits. The clinical relevance of empagliflozin extends beyond glycemic control, encompassing demonstrated reductions in cardiovascular mortality, hospitalization for heart failure, and progression of renal disease in high-risk patient populations. This expanded therapeutic profile has established it as a cornerstone agent in modern treatment algorithms.

The importance of understanding empagliflozin’s pharmacology lies in its unique mechanism, which necessitates consideration of physiological adaptations, potential adverse effects related to its mode of action, and specific clinical scenarios where its benefits are most pronounced. Mastery of its pharmacokinetic and pharmacodynamic properties is essential for optimizing therapeutic outcomes while minimizing risks.

Learning Objectives

• Describe the molecular mechanism of action of empagliflozin as a selective SGLT2 inhibitor and its consequent physiological effects on renal glucose handling, plasma volume, and energy metabolism.
• Outline the pharmacokinetic profile of empagliflozin, including its absorption, distribution, metabolism, excretion, and the implications for dosing in special populations.
• Identify the approved clinical indications for empagliflozin, including its role in type 2 diabetes management, cardiovascular risk reduction, heart failure treatment, and chronic kidney disease.
• Analyze the spectrum of adverse effects associated with empagliflozin therapy, with particular emphasis on genitourinary infections, volume depletion, euglycemic diabetic ketoacidosis, and potential long-term bone and renal effects.
• Evaluate significant drug interactions and contraindications, and apply special considerations for its use in pregnancy, lactation, pediatric and geriatric patients, and those with renal or hepatic impairment.

Classification

Empagliflozin is classified primarily within two overlapping frameworks: therapeutic and chemical.

Therapeutic Classification

The primary therapeutic classification is as an antihyperglycemic agent or antidiabetic drug. More specifically, it belongs to the pharmacologic class of sodium-glucose cotransporter 2 (SGLT2) inhibitors. This class is also referred to as gliflozins. Within this class, empagliflozin is distinguished by its high selectivity for SGLT2 over SGLT1, which may influence its efficacy and side effect profile.

Chemical Classification

Chemically, empagliflozin is a C-aryl glucoside derivative. Its systematic name is (1S)-1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol. The molecular structure features a glucose moiety linked to a diarylmethane group containing a chlorophenyl and a phenoxy tetrahydrofuran ring. This specific structure is responsible for its high affinity and selectivity for the SGLT2 protein. The molecular weight is 450.9 g/mol. It is formulated as the pure compound and is not a prodrug.

Mechanism of Action

The mechanism of action of empagliflozin is rooted in the physiology of renal glucose reabsorption, representing a unique insulin-independent pathway for lowering plasma glucose.

Molecular and Cellular Mechanisms

Under normal physiological conditions, approximately 180 grams of glucose are filtered daily by the renal glomeruli. Virtually all of this filtered glucose is reabsorbed in the proximal convoluted tubule via sodium-glucose cotransporters. The high-capacity, low-affinity SGLT2, located in the S1 segment of the proximal tubule, is responsible for reabsorbing about 90% of the filtered glucose load. The remaining 10% is handled by the high-affinity, low-capacity SGLT1 transporter in the more distal S3 segment.

Empagliflozin acts as a potent, competitive, and highly selective inhibitor of SGLT2. By binding to SGLT2 with an inhibitory concentration (IC₅₀) in the low nanomolar range, it blocks the cotransport of sodium and glucose from the tubular lumen into the proximal tubular epithelial cells. This inhibition is highly selective, with empagliflozin demonstrating approximately 2500-fold greater affinity for SGLT2 compared to SGLT1. The primary consequence is a reduction in the renal threshold for glucose (RT_G), which normally lies at a plasma glucose concentration of approximately 180-200 mg/dL. Empagliflozin lowers the RT_G to around 70-90 mg/dL, resulting in significant glucosuria.

Systemic Pharmacodynamic Effects

The inhibition of renal glucose reabsorption initiates a cascade of systemic effects:

• Glycemic Control: The excretion of glucose in the urine (typically 60-100 grams per day) creates a calorie deficit and directly lowers plasma glucose concentrations. This effect is independent of insulin secretion or sensitivity, making it effective even in advanced stages of type 2 diabetes with significant beta-cell dysfunction.
• Hemodynamic and Metabolic Effects: The osmotic diuresis induced by glucosuria leads to a mild reduction in plasma volume and preload, contributing to a modest lowering of blood pressure (typically 3-5 mmHg systolic). The natriuresis associated with SGLT2 inhibition may also have beneficial effects on arterial stiffness and afterload. Furthermore, the shift in substrate utilization from glucose to lipids and ketones, coupled with weight loss from calorie excretion, improves overall metabolic parameters.
• Cardiorenal Effects: Beyond glucose, the mechanisms underlying empagliflozin’s cardiorenal benefits are multifactorial and include:
  • Improved ventricular loading conditions due to reduced preload and afterload.
  • Enhanced erythropoiesis and improved oxygen delivery, potentially linked to a mild, adaptive tubuloglomerular feedback-mediated renal hypoxia.
  • Shift in myocardial and renal fuel metabolism from fatty acids and glucose to ketone bodies, which may be a more efficient fuel source in stressed tissues.
  • Reduction in intraglomerular pressure via afferent arteriolar constriction, mediated by tubuloglomerular feedback in response to increased sodium delivery to the macula densa, providing renoprotection.
  • Anti-inflammatory and anti-fibrotic effects observed in preclinical models.

Pharmacokinetics

The pharmacokinetic profile of empagliflozin is characterized by predictable absorption, extensive distribution, and metabolism primarily via glucuronidation, with renal excretion playing a key role in its elimination.

Absorption

Following oral administration, empagliflozin is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations (C_max) are achieved at a median time (T_max) of approximately 1.5 hours post-dose. The absolute oral bioavailability is estimated to be high, at around 78%. Food intake does not have a clinically significant impact on absorption; the area under the curve (AUC) and C_max are not meaningfully altered when administered with a high-fat, high-calorie meal. Therefore, empagliflozin can be taken without regard to meals, which may improve medication adherence.

Distribution

Empagliflozin demonstrates a large apparent volume of distribution, suggesting extensive tissue distribution. In vitro plasma protein binding is approximately 86%, primarily to albumin. The drug is not considered to be highly protein-bound in a manner that would lead to significant displacement interactions. The extent of distribution into specific compartments, such as the kidneys where its target resides, is substantial.

Metabolism

Empagliflozin undergoes extensive hepatic metabolism, but not via the cytochrome P450 (CYP) system. The primary metabolic pathways are glucuronidation by uridine 5′-diphospho-glucuronosyltransferase (UGT) enzymes, specifically UGT1A3, UGT1A8, UGT1A9, and UGT2B7. The major metabolites are the inactive glucuronide conjugates at the phenolic hydroxyl groups (2-O-, 3-O-, and 6-O-glucuronides). These metabolites account for the majority of the drug-related material in plasma. Oxidative metabolism by CYP enzymes is minimal, accounting for less than 10% of the total clearance, which minimizes the potential for pharmacokinetic drug interactions mediated by CYP inhibition or induction.

Excretion

Elimination occurs via both renal and hepatic pathways. Following a single oral dose of radiolabeled empagliflozin, approximately 54% of the dose is recovered in feces and 41% in urine. In the urine, the majority is excreted as metabolites, with only 11.5% of the dose recovered as unchanged parent drug. The renal clearance of empagliflozin (approximately 140 mL/min) exceeds the glomerular filtration rate, indicating active tubular secretion in addition to glomerular filtration. The effective half-life (t_1/2) of empagliflozin is approximately 12.4 hours, supporting once-daily dosing.

Dosing Considerations

The standard recommended dose for most indications is 10 mg once daily. A dose increase to 25 mg once daily may be considered for patients who require additional glycemic control, as the higher dose provides a modestly greater glucosuric effect. Dosing adjustments are not required based on age, gender, body weight, or mild to moderate hepatic impairment. However, specific considerations apply to renal function, as detailed in the Special Considerations section. The pharmacokinetics are linear and dose-proportional over the clinical dose range.

Therapeutic Uses/Clinical Applications

Empagliflozin has received regulatory approval for several indications based on robust outcomes from large-scale clinical trials.

Approved Indications

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is effective as monotherapy or in combination with other antihyperglycemic agents, including metformin, sulfonylureas, DPP-4 inhibitors, insulin, and GLP-1 receptor agonists.
• Reduction of Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease: This indication is based on the landmark EMPA-REG OUTCOME trial, which demonstrated a 38% relative risk reduction in cardiovascular death and a 32% reduction in all-cause mortality in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
• Heart Failure: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. This includes patients with heart failure with reduced ejection fraction (HFrEF), as shown in the EMPEROR-Reduced trial, and heart failure with preserved ejection fraction (HFpEF), as shown in the EMPEROR-Preserved trial. This benefit is observed irrespective of the presence of type 2 diabetes.
• Chronic Kidney Disease: To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. The EMPA-KIDNEY trial supported this broad indication in patients with eGFR as low as 20 mL/min/1.73 m² and significant albuminuria.

Off-Label Uses

While not formally approved, emerging evidence and clinical practice patterns support the investigation and occasional use of empagliflozin in other contexts. These uses should be considered experimental or based on extrapolation from class effects and require careful clinical judgment.

• Polycystic Ovary Syndrome (PCOS): Potential use to address insulin resistance and promote weight loss, though data are limited compared to traditional agents like metformin.
• Type 1 Diabetes Mellitus: Investigational use as an adjunct to insulin to improve glycemic control and reduce insulin doses. This use is associated with a markedly increased risk of diabetic ketoacidosis (DKA) and is not approved; if considered, it requires extreme caution, meticulous monitoring, and patient education.
• Non-alcoholic Fatty Liver Disease (NAFLD): Potential for reducing liver fat content and improving hepatic inflammation due to its effects on weight and metabolism, though dedicated outcomes trials are ongoing.

Adverse Effects

The adverse effect profile of empagliflozin is largely predictable from its mechanism of action and can be categorized by frequency and severity.

Common Side Effects

These effects are generally mild to moderate in intensity and often diminish over time.

• Genitourinary Infections: The increased glucose concentration in the urine creates a favorable environment for microbial growth. Genital mycotic infections (e.g., vulvovaginal candidiasis in women, balanitis in men) occur in approximately 5-10% of patients, with higher rates in females, patients with a prior history, and uncircumcised males. Urinary tract infections (UTIs) are also reported more frequently (≈8%) compared to placebo.
• Volume Depletion-Related Effects: The osmotic diuretic effect can lead to reduced intravascular volume, manifesting as symptoms such as postural dizziness, orthostatic hypotension, thirst, and, in some cases, transient increases in serum creatinine. The risk is heightened in the elderly, those on diuretics, and patients with renal impairment or low systolic blood pressure.
• Increased Urination: Polyuria and nocturia are common initial effects due to glucosuria.
• Dyslipidemia: Small increases in low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels have been observed, with a net effect on the LDL-C/HDL-C ratio that is generally neutral.

Serious/Rare Adverse Reactions

• Euglycemic Diabetic Ketoacidosis (euDKA): This is a potentially life-threatening metabolic complication characterized by ketoacidosis with blood glucose levels often below 250 mg/dL. The risk, while low in absolute terms, is increased in clinical scenarios associated with relative insulin deficiency and increased glucagon secretion (e.g., acute illness, surgery, prolonged fasting, excessive alcohol intake, insulin dose reduction). The mechanism involves a combination of reduced insulin dose (due to improved glycemia), increased glucagon, and enhanced renal ketone reabsorption. Symptoms may include nausea, vomiting, abdominal pain, malaise, and shortness of breath.
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): A rare but serious, life-threatening necrotizing infection of the perineum and genital region has been reported in patients taking SGLT2 inhibitors, including empagliflozin. It requires urgent surgical debridement and broad-spectrum antibiotics.
• Acute Kidney Injury (AKI): Cases of AKI, sometimes requiring hospitalization and dialysis, have been reported. Contributing factors may include volume depletion, concomitant use of diuretics or NSAIDs, and pre-existing renal impairment.
• Lower Limb Amputation: Data from a trial with a different SGLT2 inhibitor (canagliflozin) suggested an increased risk of lower limb amputations. While the signal was not confirmed in large cardiovascular outcomes trials for empagliflozin, a potential class effect cannot be entirely ruled out. Vigilance is recommended in patients with prior amputation, peripheral vascular disease, neuropathy, or diabetic foot ulcers.
• Bone Fractures: An increased risk of bone fracture was observed with canagliflozin. Clinical trials with empagliflozin have not shown a significant increase in fracture risk, but long-term effects on bone mineral density, possibly related to weight loss and mild calcium and phosphate excretion, warrant monitoring in at-risk populations.
• Hypersensitivity Reactions: Rare cases of angioedema and urticaria have been reported.

Black Box Warnings

Empagliflozin does not currently carry a black box warning from the U.S. Food and Drug Administration (FDA). However, the prescribing information contains prominent warnings for the following serious risks, which are often considered analogous to black box warnings in clinical practice:

• Euglycemic Diabetic Ketoacidosis: A bolded warning advises assessing for risk factors and monitoring for signs and symptoms, especially during acute metabolic stress.
• Lower Limb Amputation: While not a black box, a warning is included based on data from another SGLT2 inhibitor, advising monitoring in at-risk patients.

Drug Interactions

The drug interaction profile of empagliflozin is relatively favorable due to its minimal metabolism by CYP enzymes. However, pharmacodynamic interactions are significant.

Major Drug-Drug Interactions

• Diuretics (Loop and Thiazide): Concomitant use increases the risk of volume depletion and hypotension due to additive diuretic effects. Blood pressure, renal function, and volume status should be monitored, especially during initiation.
• Insulin and Insulin Secretagogues (Sulfonylureas, Meglitinides): The glucose-lowering effects of empagliflozin are additive with insulin and insulin secretagogues. This combination increases the risk of hypoglycemia. A reduction in the dose of insulin or secretagogue may be necessary to mitigate this risk.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs may impair renal function and reduce the efficacy of diuretics, potentially increasing the risk of acute kidney injury when combined with empagliflozin, particularly in volume-depleted states.
• Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Blockers (ARBs): While these are often used together for cardiorenal protection, the combination can potentiate the risk of hyperkalemia, especially in patients with renal impairment or those on potassium-sparing diuretics.
• Potassium-Sparing Diuretics (e.g., Spironolactone, Eplerenone, Amiloride): May increase the risk of hyperkalemia.
• Rifampin: This potent inducer of UGT enzymes may decrease systemic exposure to empagliflozin by increasing its glucuronidation. The clinical significance is uncertain, but monitoring for reduced glycemic efficacy may be prudent.

Contraindications

• History of Serious Hypersensitivity Reaction: Contraindicated in patients with a history of anaphylaxis or severe cutaneous adverse reactions to empagliflozin or any product component.
• Severe Renal Impairment, End-Stage Renal Disease, or Dialysis: Empagliflozin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) persistently below 20 mL/min/1.73 m², as its efficacy is dependent on renal function. It is also not recommended in patients on dialysis. Note that the threshold for initiation differs from the threshold for discontinuation; therapy may be continued if eGFR falls below 20 mL/min/1.73 m² during treatment if the patient is deriving benefit.
• Diabetic Ketoacidosis: Contraindicated for the treatment of diabetic ketoacidosis, as it is not effective for this acute condition and may exacerbate risk factors.

Special Considerations

Pregnancy and Lactation

Pregnancy: Empagliflozin is not recommended during the second and third trimesters of pregnancy. Data from animal studies have shown adverse renal effects in offspring when exposure occurs during periods of renal development, which corresponds to the late second and third trimesters in humans. There are no adequate and well-controlled studies in pregnant women. Given that the management of diabetes in pregnancy typically requires tight glycemic control, insulin remains the standard of care due to its long-established safety profile.

Lactation: It is not known whether empagliflozin is excreted in human milk. Data from animal studies indicate excretion in milk. Given the potential for serious adverse reactions in the nursing infant, including effects on renal development, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric and Geriatric Considerations

Pediatric Use: The safety and effectiveness of empagliflozin in pediatric patients (under 18 years of age) have not been established. Its use is not approved in this population.

Geriatric Use: No overall differences in safety or efficacy were observed between patients aged 65 and older and younger patients in clinical studies. However, greater sensitivity in some older individuals cannot be ruled out. Elderly patients are more likely to have decreased renal function and are at higher risk for volume depletion, hypotension, and renal impairment. Renal function should be assessed prior to initiation and monitored periodically. The starting dose does not require adjustment based on age alone, but careful consideration of renal function is paramount.

Renal Impairment

Renal function is a critical determinant of empagliflozin’s efficacy and safety profile.

• Initiation: Empagliflozin is recommended for initiation in patients with an eGFR ≥20 mL/min/1.73 m² for the CKD indication, and typically ≥45 mL/min/1.73 m² for the diabetes indication to ensure a meaningful glucosuric effect. The glycemic efficacy diminishes as eGFR declines.
• Monitoring and Discontinuation: Renal function (eGFR) should be assessed prior to initiation and monitored periodically thereafter. For the treatment of diabetes, discontinuation is recommended if eGFR falls persistently below 45 mL/min/1.73 m², as glycemic efficacy is significantly reduced. For cardiorenal indications (heart failure, CKD), therapy may be continued for organ protection even if eGFR falls below these thresholds, as benefits on heart failure hospitalization and renal progression have been demonstrated in lower eGFR ranges.
• Contraindication: As noted, it is contraindicated in patients with eGFR <20 mL/min/1.73 m² and those on dialysis.

Hepatic Impairment

Pharmacokinetic studies indicate that mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment does not result in clinically significant changes in empagliflozin exposure. Therefore, no dose adjustment is necessary in these populations. The pharmacokinetics of empagliflozin in patients with severe hepatic impairment (Child-Pugh class C) have not been studied, and its use in this population is not recommended due to a lack of data and the potential for altered metabolic and volume status.

Summary/Key Points

• Empagliflozin is a highly selective SGLT2 inhibitor that lowers plasma glucose by inducing renal glucosuria, an effect independent of insulin.
• Its mechanism confers multiple beneficial effects beyond glycemia, including modest blood pressure reduction, weight loss, and, most importantly, significant reductions in cardiovascular death, heart failure hospitalizations, and progression of chronic kidney disease, as demonstrated in large outcome trials.
• The pharmacokinetic profile features rapid oral absorption unaffected by food, metabolism primarily via UGT-mediated glucuronidation (minimizing CYP-based interactions), and elimination via both renal and fecal routes, supporting once-daily dosing.
• Common adverse effects are related to its mechanism and include genital mycotic infections, urinary tract infections, and volume depletion. Serious risks requiring vigilance include euglycemic diabetic ketoacidosis, necrotizing fasciitis of the perineum, and acute kidney injury.
• Significant drug interactions are primarily pharmacodynamic, notably with diuretics (risk of volume depletion) and insulin/secretagogues (risk of hypoglycemia).
• Use is contraindicated in severe renal impairment (eGFR <20 mL/min/1.73 m²) and end-stage renal disease. Careful assessment of renal function is mandatory before and during therapy. No dose adjustment is needed for mild to moderate hepatic impairment.
• Empagliflozin is not recommended during the second and third trimesters of pregnancy or during lactation. Its safety and efficacy in pediatric patients have not been established.

Clinical Pearls

• Consider empagliflozin early in the treatment algorithm for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure (regardless of ejection fraction), or chronic kidney disease, given its proven mortality and morbidity benefits.
• Educate all patients starting empagliflozin about the symptoms of euglycemic DKA (nausea, vomiting, malaise, abdominal pain), emphasizing that they can occur even with normal or only slightly elevated blood glucose levels. Advise them to check for ketones during acute illness and to seek immediate medical attention if symptoms arise.
• To mitigate the risk of genital infections, advise patients on proper hygiene, including keeping the genital area clean and dry. Pre-emptively treat recurrent infections in susceptible individuals.
• Monitor volume status and renal function, especially during initiation, in elderly patients, and when used concomitantly with diuretics, ACE inhibitors, ARBs, or NSAIDs. A transient rise in serum creatinine of up to 30% may be observed and often stabilizes; however, a persistent or greater rise warrants evaluation.
• For patients also on insulin or sulfonylureas, proactively reduce the dose of these agents upon initiating empagliflozin to prevent hypoglycemia, as the glucosuric effect is immediate.
• Do not initiate therapy for glycemic control if the patient’s eGFR is below 45 mL/min/1.73 m², as efficacy is limited. However, for cardiorenal protection, initiation may be considered at lower eGFR levels (≥20 mL/min/1.73 m²) based on recent trial evidence, and therapy may be continued for organ benefit even if eGFR declines during treatment.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.